A pharma maker is recalling one lot of an allergy medication because the bottles mistakenly contain this medication.
A pharma maker is recalling one lot of an allergy medication because the bottles mistakenly contain a high blood pressure medication.
Camber Pharmaceuticals is voluntarily recalling the lot of 10 mg, 30-count bottles of Montelukast Sodium tablets, which actually contain 90 tablets of Losartan Potassium Tablets, 50 mg.
Related: Cancer risk found with common blood pressure med
“This tablet mix-up may pose a safety risk as taking losartan tablets when not prescribed has the potential to cause renal dysfunction, elevated potassium levels and low blood pressure,” FDA said in a statement.
The risk is especially high for pregnant women taking the allergy and asthma medication montelukast because losartan, used to treat high blood pressure, could harm or kill the fetus.
“We want to ensure that patients who take montelukast are aware of this recall due to the serious risks associated with taking losartan in its place,” said Donald D. Ashley, director of the office of compliance in the FDA’s center for drug evaluation and research, in the FDA statement. “Patients who take prescription drugs expect and deserve to have the medication their doctor prescribed.”
Related: Top 3 drug alerts of 2018
FDA recommends that consumers with the recalled product should contact their healthcare provider or pharmacist immediately.
The recall is not related to the recent valsartan recalls that were due to an impurity, N-nitrosodimethylamine (NDMA).
Recalled montelukast sodium tablets include the lot number: MON17384, and expiration date 12/31/2019.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More